David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in kidney cancer and developing biomarkers for anti-PD-L1 agents.
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in kidney cancer and developing biomarkers for anti-PD-L1 agents.
Clinical Pearls:
A tumor that uses PD-L1 as a defense might be more likely to respond to an agent that targets the interaction between the T cell and the tumor
In kidney cancers, there are patients that do not express PD-L1 but are responding to anti-PD-L1 agents
Tumors in kidney cancers are heterogeneous and different aspects of the tumor will express PD-L1 while other places in the tumor will not
Researchers are looking at the difference between the primary tumors and their metastases in terms of PD-L1 expression to try to determine which patients will benefit the most from treatment
